Derivation Web

v0.1 · api

Chain for claim_16b21048198c4532

8 nodes. Root first; inputs below.

depth 0 · claim · via classify
claim_16b21048198c4532
**Selected angle:** `source`

## One-sentence thesis

The cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle.

**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The surprise is the bounded heterogenei…
sha256 702acfd75ccd519d…
depth 1 · source
source_548c9b986b2e4fc6
**Selected angle:** `source`

## One-sentence thesis

The cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The surprise is the bounded heterogene…
sha256 f009f6dfeaf78ee6…
depth 1 · source
source_c1706af9699140eb
{"publication_id": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "traces": [{"candidate_sources": [{"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": null}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": null}, {"…
sha256 166c14185712e2cc…
depth 1 · source
source_57b49d98a6ae4b2c
{"content_hash": null, "edges": [{"from": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "to": "claim_1", "type": "contains_claim"}, {"from": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "to": "claim_2", "type": "contains_claim"}, {"from": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "to": "claim_3", "type": "contains_claim"}, {"from": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "to": "claim_4", "type": "contains_clai…
sha256 338dc911d8ef0df0…
depth 1 · source
source_6170c49549ba4b36
{"contradictions": [], "limitations": ["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "scre…
sha256 c27dd6761f9aa7a5…
depth 1 · source
source_a62e3aea5ff0447e
study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials,not extracted,not extracted,not …
sha256 6110c727a6c56768…
depth 1 · source
source_3f8410ffdeb54c07
{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "sources": [{"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatm…
sha256 a6de3cb19062c2db…
depth 1 · source
source_8a2bb1b6e7394bab
{"decision": "accept", "gate_failures": [], "notes": ["accepted and queued for publish"], "review_recommendation": "accept"}
sha256 030e80c77c942caf…